COMMUNIQUÉS West-GlobeNewswire

Les détecteurs Focus HD et le système de radiologie mobile DRX-Rise de Carestream reçoivent l’autorisation de marquage CE par l’Union européenne

10/01/2025 - 15:11

ROCHESTER, New York, 10 janv. 2025 (GLOBE NEWSWIRE) -- Carestream Health a annoncé ce jour avoir reçu l’autorisation de marquage CE de l’Union européenne pour ses détecteurs Focus HD et son système de radiologie mobile [...]

Upgrade of revenue and operating profit guidance

10/01/2025 - 09:48

ANNOUNCEMENT NO. 286 10 January 2025 Upgrade of revenue and operating profit guidance ChemoMetec sustained its positive performance in the second quarter of 2024/25 with better-than-expected sales and order intake. The [...]

PCI Biotech: Employee share option scheme in connection with promotion of new CSO

10/01/2025 - 10:24

Oslo, 10 January 2025 - PCI Biotech (OSE: PCIB), today announced that the Board of Directors has granted share options to Morten Luhr who has been promoted to Chief Scientific Officer (CSO) from January 2025. Anders [...]

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

10/01/2025 - 12:00

Grew full-year revenue to an estimated $71.3 million, an increase of 45% LOUISVILLE, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its [...]

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

10/01/2025 - 12:00

- Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile - Promising clinical activity observed in patients with triple-negative breast cancer (TNBC) previously [...]

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

10/01/2025 - 12:02

Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ET CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical [...]

PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing

10/01/2025 - 12:05

MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled [...]

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA

10/01/2025 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS ANNOUNCEMENT [...]

Partnering to Save Lives, NMDP and the American Football Coaches Association Promote Student Athlete Philanthropy

09/01/2025 - 21:30

AFCA’s Support of NMDP Get in the Game Invites College Coaches and Student Athletes to Help Give More Patients a Second Chance at Life Through Blood Stem Cell Donations MINNEAPOLIS, Jan. 09, 2025 (GLOBE NEWSWIRE) -- [...]

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09/01/2025 - 21:38

NAARDEN, the Netherlands and MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, [...]

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

09/01/2025 - 22:00

Priority programs – NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis – set foundation for significant, near-term value creation Phase 3 HAELO study [...]

BioV Life Science and Regenerative Medicine International Summit Successfully Concludes, Leading the Future of Regenerative Medicine

09/01/2025 - 22:00

Los Angeles, CA, Jan. 09, 2025 (GLOBE NEWSWIRE) -- On December 22, 2024, the "BioV Life Science and Regenerative Medicine International Summit," a significant event in the life sciences field at the end of 2024, [...]

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

09/01/2025 - 22:00

Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary data readouts for [...]

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

09/01/2025 - 22:00

TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company [...]

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024

09/01/2025 - 22:05

PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]

ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025

09/01/2025 - 22:05

SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on Thursday, January 30, 2025, [...]

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

09/01/2025 - 22:15

Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 09 janv. 2025 (GLOBE NEWSWIRE) -- Paris, France, le 9 janvier 2025 Place de cotation : [...]

Voting Rights and Shares Capital of the Company

09/01/2025 - 22:15

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Jan. 09, 2025 (GLOBE NEWSWIRE [...]

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

09/01/2025 - 22:30

SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm , a nationally renowned sports [...]